Physician profile
Peter Byrne
NPI 1144693532
$55,890.52
in general payments reported to CMS, 2019-2025
34 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $1,612 · 2023: $12K · 2024: $26K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $12K · Travel and Lodging: $7,351 · Consulting Fee: $4,500 · Education: $83.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,450.00 |
| Food and Beverage | $12,489.55 |
| Travel and Lodging | $7,350.76 |
| Consulting Fee | $4,500.00 |
| Education | $83.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25,508.66 | 2023-2025 | Omvoh |
| Abbvie INC. | $21,027.16 | 2021-2025 | |
| Janssen Biotech, INC. | $2,712.96 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,359.49 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $962.48 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $540.44 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $477.12 | 2022-2025 | |
| Pfizer INC. | $371.17 | 2022-2025 | |
| Celgene Corporation | $320.32 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $315.97 | 2022-2025 | |
| Novo Nordisk INC | $282.11 | 2023-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $219.82 | 2022-2025 | Ocaliva |
| Qol Medical, LLC | $191.89 | 2023-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $185.43 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $160.35 | 2025 | Vowst, Zenpep |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $144.52 | 2025 | Livmarli |
| Amgen INC. | $132.22 | 2025 | Uplizna |
| Regeneron Healthcare Solutions, INC. | $125.16 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $117.76 | 2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $103.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $102.73 | 2023-2025 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $95.64 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $92.48 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $71.72 | 2023-2025 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.00 | 2023 | Cyltezo |
| Mylan Institutional INC. | $38.12 | 2023 | Hulio |
| Redhill Biopharma INC. | $31.52 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Celltrion USA INC. | $28.07 | 2023 | Yuflyma |
| Lucid Diagnostics INC. | $22.16 | 2024 | |
| Madrigal Pharmaceuticals | $18.50 | 2025 | Rezdiffra |
| Organon LLC | $16.21 | 2023 | Renflexis |
| Albireo Pharma, INC. | $15.35 | 2023 | Bylvay |
| Orphalan INC | $15.31 | 2025 | Cuvrior |
| Braintree Laboratories, INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.